Perfil
Timothy Sullivan worked as a Senior Director-External Research & Development at Pfizer Inc. from 2015 to 2017.
Prior to that, he was the Immunology Director at ChemoCentryx, Inc. from 2010 to 2012, and then worked as the Director-New Frontier Science at Takeda Pharmaceutical Co., Ltd.
from 2012 to 2015.
From 2017 to 2020, he served as the Vice President-Business Development at Arcus Biosciences, Inc. Sullivan received his undergraduate degree from the University of Notre Dame and his doctorate from the University of California, Berkeley.
Antiguos cargos conocidos de Timothy Sullivan.
| Empresas | Cargo | Fin |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01/05/2020 |
| PFIZER, INC. | Director Técnico/Científico/I+D | 01/01/2017 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01/06/2015 |
| CHEMOCENTRYX, INC. | Corporate Officer/Principal | 01/12/2012 |
Formación de Timothy Sullivan.
| University of Notre Dame | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ARCUS BIOSCIENCES, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Empresas privadas | 1 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Timothy Sullivan